Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter, randomized, double-blind, placebo controlled 36 week study to evaluate the efficacy and safety of extended release (ER) niacin/laropiprant in patients with type 2 diabetes.

Next Previous
Trial Profile

A multicenter, randomized, double-blind, placebo controlled 36 week study to evaluate the efficacy and safety of extended release (ER) niacin/laropiprant in patients with type 2 diabetes.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 May 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Niacin/laropiprant (Primary)
  • Indications Hypercholesterolaemia; Hyperlipidaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Merck & Co

    • Most Recent Events

    • 13 May 2019 Trial completed in Finland (End date: 5 Aug 2008).
    • 24 Mar 2012 This trial is recruiting in (Finland) as reported by European Clinical Trials Database record.
    • 26 Sep 2010 Results have been presented at the 46th Annual Meeting of the European Association for the Study of Diabetes.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top